Commodore Capital LP Akero Therapeutics, Inc. Transaction History

Commodore Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$41.19 - $52.25 $45.7 Million - $58 Million	-1,110,000 Reduced 66.27%	565,000 $28.6 Million
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $32.6 Million - $50.3 Million	885,000 Added 112.03%	1,675,000 $78.2 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $9.43 Million - $12.7 Million	252,924 Added 47.09%	790,000 $30.2 Million
Q4 2022 Feb 14, 2023	SELL	$33.44 - $54.8 $6.9 Million - $11.3 Million	-206,396 Reduced 27.76%	537,076 $29.4 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $7.55 Million - $25.3 Million	743,472 New	743,472 $25.3 Million

194

74.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.37B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.